Literature DB >> 3348967

Clinical features and course of type A and type B vitiligo.

M Koga1, T Tango.   

Abstract

Four hundred and eighty one cases of vitiligo (acquired idiopathic depigmentation) were studied clinically. They were divided into two types, type B, in which depigmented patches are confined to a definite dermatome in the same manner as herpes zoster, and type A, which included all cases of vitiligo not classified as type B. The ratio of type A:type B was approximately 3:I. Onset of type A vitiligo could occur at any age, whereas type B generally affected the young. The activity of type B vitiligo usually ceased after one year, following rapid spread over the particular dermatomal area. However, in type A vitiligo new depigmented patches continued to appear throughout the patients' lives. Association with halo naevus and Köbner's phenomenon were observed exclusively in type A. Association with diseases with a proven or suggested allergic or immunological aetiology was more often found in type A. These findings support our hypothesis that type A and type B vitiligo have a different pathogenesis and that autoimmune mechanisms play a role only in type A.

Entities:  

Mesh:

Year:  1988        PMID: 3348967     DOI: 10.1111/j.1365-2133.1988.tb01778.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

Review 1.  Highlights in pathogenesis of vitiligo.

Authors:  Ghada F Mohammed; Amal Ha Gomaa; Mohammed Saleh Al-Dhubaibi
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

2.  [Vitiligo: Clinical presentation and pathogenesis].

Authors:  M Schild; M Meurer
Journal:  Hautarzt       Date:  2016-02       Impact factor: 0.751

Review 3.  The etiology and molecular genetics of human pigmentation disorders.

Authors:  Laura L Baxter; William J Pavan
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2012-05-17       Impact factor: 5.814

4.  Clinical course of segmental vitiligo: a retrospective study of eighty-seven patients.

Authors:  Ji-Hye Park; Mi-Young Jung; Joo-Heung Lee; Jun-Mo Yang; Dong-Youn Lee; Kelly K Park
Journal:  Ann Dermatol       Date:  2014-02-17       Impact factor: 1.444

5.  Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference.

Authors:  K Ezzedine; H W Lim; T Suzuki; I Katayama; I Hamzavi; C C E Lan; B K Goh; T Anbar; C Silva de Castro; A Y Lee; D Parsad; N van Geel; I C Le Poole; N Oiso; L Benzekri; R Spritz; Y Gauthier; S K Hann; M Picardo; A Taieb
Journal:  Pigment Cell Melanoma Res       Date:  2012-05       Impact factor: 4.693

6.  When are laboratory tests indicated in patients with vitiligo?

Authors:  Marina Rodríguez-Martín; Miguel Sáez; Nayra Merino de Paz; Patricia Contreras Ferrer; Mar Pestana Eliche; Beatriz Rodríguez-Martín; Antonio Noda Cabrera
Journal:  Dermatoendocrinol       Date:  2012-01-01

7.  Anti-thyroid peroxidase antibody in vitiligo: a prevalence study.

Authors:  R Dash; A Mohapatra; B S Manjunathswamy
Journal:  J Thyroid Res       Date:  2015-01-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.